Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts

Identifying miRNA in Biofluids to be Applied as Robust Biomarkers for Disease, Toxicology or Injury Studies – The case of Minimally Invasive Colorectal Cancer Detection

Peter Mouritzen, Exiqon, speaking at Genomics Research Europe 2012
Date Posted: Thursday, January 24, 2013
Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

Exiqon Licenses Biomarkers From Aarhus University Hospital
Exiqon A/S has exclusively licensed prostate cancer biomarkers discovered and validated by Aarhus University Hospital, Department of Molecular Medicine (MOMA).
Wednesday, December 03, 2014
Redefining High Risk Patients With Stage II Colon Cancer
microRNA-21 identified as an independent prognostic biomarker.
Friday, September 12, 2014
Exiqon Licenses Locked Nucleic Acids for Infectious Disease Diagnostics to BD
BD will use Exiqon's proprietary LNA™ technology in defined products for infectious disease diagnostics.
Wednesday, June 23, 2010
Exiqon and MultiD Sign Development and Distribution Agreement for microRNA qPCR Analysis Solution
Agreement incorporates a specifically adapted version of the GenEx qPCR analysis software for Exiqon's new microRNA qPCR platform.
Wednesday, May 26, 2010
Exiqon Appoints President and General Manager of new US Operations
Michael Kallelis will have the overall responsibility for launching and operating Exiqon’s US office to be located in the Boston area.
Friday, January 06, 2006
Exiqon Wins Ernst & Young Entrepeneur of the Year Award
Exiqon selected as winner in the BIOTECH 2005 category.
Tuesday, November 22, 2005
Exiqon A/S appoints permanent CEO

Monday, February 24, 2003
Scientific News
Vital Step in Stem Cell Growth Revealed
Salk scientists' finding could aid regenerative and cancer therapies.
Foreign Antibodies Mobilize Immune System to Fight Cancer
A mouse’s T cells can be primed to attack and eliminate a malignant tumor by injecting antibodies from another mouse with resistance to the tumor, as well as by activating certain signaling cells, a study has found.
UNC Researchers Create DNA Repair Map of the Entire Human Genome
The new experimental assay can help scientists find the precise locations of repair of DNA damage caused by UV radiation and common chemotherapies.
Naked Mole-Rats’ Anti-Cancer Gene
Researchers have found that the gene which gives naked mole-rats’ their natural resistance to cancer is unique among mammals.
Telomere Changes Predict Cancer
A distinct pattern in the changing length of blood telomeres, the protective end caps on our DNA strands, can predict cancer many years before actual diagnosis, according to a new study from Northwestern Medicine in collaboration with Harvard University.
Souped-up Remote Control Switches Behaviors On-and-Off in Mice
BRAIN Initiative yields chemical-genetic tool with push-pull capabilities.
DNA Suggests All Early Eskimos Migrated from North Slope
First evidence to genetically tie all Inuit populations to Alaska's North Slope.
Odd Histone Helps Suppress Jumping Genes in Stem Cells, Study Says
Research reveals a basic mechanism by which epigenetics, or the control of inherited traits through means other than DNA, works.
The Genetics Behind Abdominal Pigmentation in Drosophila melanogaster
This study by researchers at the North Carolina State University provides evidence that genetic variation at a number of steps in regulatory, developmental, and transport pathways may contribute to natural variation in abdominal pigmentation.
NIH-funded Study Points Way Forward for Retinal Disease Gene Therapy
Benefits for Leber congenital amaurosis peak after one to three years, then diminish.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters